Insider Selling: Johnson & Johnson (NYSE:JNJ) EVP Sells $4,276,630.00 in Stock

Johnson & Johnson (NYSE:JNJ) EVP Ashley Mcevoy sold 29,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $147.47, for a total transaction of $4,276,630.00. Following the completion of the sale, the executive vice president now directly owns 21,682 shares of the company’s stock, valued at $3,197,444.54. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Shares of JNJ opened at $146.84 on Friday. Johnson & Johnson has a 12-month low of $109.16 and a 12-month high of $157.00. The business’s fifty day moving average is $144.06 and its 200 day moving average is $144.13. The company has a quick ratio of 1.05, a current ratio of 1.25 and a debt-to-equity ratio of 0.40. The stock has a market cap of $386.60 billion, a P/E ratio of 21.47, a P/E/G ratio of 3.25 and a beta of 0.69.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Thursday, July 16th. The company reported $1.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.50 by $0.17. The firm had revenue of $18.34 billion during the quarter, compared to analyst estimates of $17.73 billion. Johnson & Johnson had a return on equity of 35.21% and a net margin of 22.69%. The business’s revenue was down 10.8% compared to the same quarter last year. During the same period last year, the firm posted $2.58 EPS. On average, analysts expect that Johnson & Johnson will post 7.85 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be paid a $1.01 dividend. The ex-dividend date of this dividend is Monday, August 24th. This represents a $4.04 annualized dividend and a yield of 2.75%. Johnson & Johnson’s dividend payout ratio is currently 46.54%.

Several institutional investors and hedge funds have recently modified their holdings of the company. Orser Capital Management LLC boosted its position in shares of Johnson & Johnson by 44.2% during the fourth quarter. Orser Capital Management LLC now owns 1,875 shares of the company’s stock valued at $272,000 after purchasing an additional 575 shares in the last quarter. Franklin Resources Inc. increased its position in Johnson & Johnson by 11.6% in the fourth quarter. Franklin Resources Inc. now owns 12,626,462 shares of the company’s stock worth $1,841,810,000 after buying an additional 1,311,739 shares in the last quarter. Vigilare Wealth Management purchased a new stake in Johnson & Johnson in the fourth quarter worth about $1,917,000. GW Henssler & Associates Ltd. increased its position in Johnson & Johnson by 3.3% in the fourth quarter. GW Henssler & Associates Ltd. now owns 2,935 shares of the company’s stock worth $428,000 after buying an additional 94 shares in the last quarter. Finally, Redhawk Wealth Advisors Inc. bought a new position in shares of Johnson & Johnson in the fourth quarter worth about $320,000. Hedge funds and other institutional investors own 68.44% of the company’s stock.

A number of equities research analysts have recently issued reports on JNJ shares. Citigroup boosted their price target on shares of Johnson & Johnson from $165.00 to $170.00 and gave the company a “buy” rating in a report on Friday, July 17th. Cantor Fitzgerald reissued a “buy” rating and issued a $168.00 target price on shares of Johnson & Johnson in a research report on Tuesday, April 28th. Raymond James boosted their target price on shares of Johnson & Johnson from $157.00 to $158.00 and gave the stock an “outperform” rating in a research report on Friday, July 17th. Barclays upped their price objective on shares of Johnson & Johnson from $173.00 to $182.00 and gave the stock an “overweight” rating in a report on Wednesday, April 29th. Finally, Wells Fargo & Co raised shares of Johnson & Johnson to a “hold” rating in a report on Wednesday, April 22nd. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and twelve have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $163.38.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

See Also: What is the Producer Price Index (PPI)?

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.